CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in SwitzerlandPRNewsWire • 03/09/23
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMPRNewsWire • 02/07/23
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in PolandPRNewsWire • 01/12/23
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch EventPRNewsWire • 01/05/23
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of DirectorsPRNewsWire • 01/03/23
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)PRNewsWire • 12/08/22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing PricePRNewsWire • 12/01/22
CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 11/14/22
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMPRNewsWire • 11/02/22
CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) RunPRNewsWire • 10/10/22
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBMGlobeNewsWire • 10/07/22
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMPRNewsWire • 09/28/22
CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)PRNewsWire • 09/23/22
CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/07/22
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 08/15/22
CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022PRNewsWire • 07/25/22
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMPRNewsWire • 06/23/22
CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual MeetingPRNewsWire • 06/08/22
CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment ConferencePRNewsWire • 05/24/22
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual MeetingPRNewsWire • 05/18/22
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 05/16/22
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)PRNewsWire • 04/28/22
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: ARECAccesswire • 04/13/22